

Fig. 1


Heparanase activity
(% of control)
100
80
60
40
20
0
control
25
50
100
170
50
250
130
239
Amount of antibody (μg)

Fig. 2


Heparanase activity
(% of control)
100
80
60
40
20
0
control
40
225
450
225
130
239
Amount of antibody (ng)

Fig. 3

FIG. 4
Western blot analysis

FIG. 5


1
2
3
4
5
6
7
8
H53MC LS2 Fr. 18, 50 ng
S1-11 + HP3/17
S1-11 +HP37/33
H53MC LS2 Fr.18 + HP3/17
H53MC LS2 Fr. 18 + HP37/33
S1-11 W/O antibody
H53MC LS2 Fr. 18 W/O Ab.
Beads only
98
62
49
38
28

FIG. 6A

FIG. 6B

FIG. 6C

FIG. 6D

x1000

FIG. 7A.

FIG. 7B.

FIG. 8A

FIG. 8B

FIG. 9A

x100



x400



FIG. 9B

FIG. 9C




Pep 10
HP201
Pep 38
HP102
1
2
Dhfr-
3
S1-11
4
5
Dhfr-
6
S1-11
62
49
38
28
p60
p45

FIG. 10

FIG. 11
Results

Group		Day 8	Day 12	Day 15	Day 18
A	Mean	7.8	90.2	375.4	613.6
PBS	SD	12.3	97.7	476.2	859.2
B	Mean	0.0	34.2	188.4	298.2
HP130	SD	0.0	42.8	165.6	111.7
C	Mean	0.0	25.3	157.5	229.3
HP37/33	SD	0.0	29.6	131.2	151.3



FIG. 12

Group	MEAN ARTHRITIC SCORE (4 legs)		
	Day 7	Day 11	Day 14
A – PBS	4.8	2.4	2.1
B – Mouse a human IgG3	4.9	3.4	2.5
C – HP3/17	4.2	2.1	1.5

FIG. 13


Th effect f HP3/17 on NOD mic survival
120
100
80
60
40
20
0
Survival
HP3/17
PBS
0
10
20
30
Age (weeks)

FIG. 14A

HP37/33



FIG. 14B
HP3/17



FIG. 15A
Epitope mapping



HP135.108

FIG. 15B



HP37/33

FIG. 16
Western blot analysis



Fig. 17A



Fig. 17B



Fig. 17C